Atypical proarrhythmia with dofetilide: Monomorphic VT and exercise-induced torsade de pointes

PACE - Pacing and Clinical Electrophysiology

Volumn 28, Issue 8, 2005, Pages 877-879

  Reiffel, James A ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE   (United States)

Author keywords

Antiarrhythmic drugs; Dofetilide; Proarrhythmia; Torsade de pointes; Ventricular tachycardia

Indexed keywords

DOFETILIDE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; ELECTROCARDIOGRAM; EXERCISE TEST; HEART ELECTROPHYSIOLOGY; HEART PROARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MALE; QT INTERVAL; QT PROLONGATION; TELEMETRY; TORSADE DES POINTES;

ADULT; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; EXERCISE TEST; HUMANS; MALE; MIDDLE AGED; PHENETHYLAMINES; SULFONAMIDES; TACHYCARDIA, VENTRICULAR; TORSADES DE POINTES; VENTRICULAR PREMATURE COMPLEXES;

EID: 27844440008     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2005.00179.x     Document Type: Article

References (11)

1. Reiffel JA. The impact of structural heart disease on the selection of class III antiarrhythmics for atrial fibrillation and flutter. Am Heart J 1998; 135:551-556.
2. Reiffel JA, Correia J. "In the absence of structural heart disease." What is it and why does it matter as regards antiarrhythmic drug therapy. Am Heart J 1994; 128:626-629.
3. Reiffel JA. Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. Am J Cardiol 1998; 82:72N-81N.
4. Reiffel JA. Drug choices in the treatment of atrial fibrillation. Am J Cardiol 2000; 85:2D-19D.
5. Tikosyn, Package Insert. Pfizer Pharmaceuticals, 2004.
6. Grines CL. Safety and effectiveness of dofetilide for conversion of atrial fibrillation and nesiritide for acute decompensation of heart failure: A report from the cardiovascular and renal advisory panel of the Food and Drug Administration. Circulation 2000; 101:E200-E201.
7. Torp-Pedersen C, Brendorp B, Kober L. Dofetilide: A class III antiarrliythmic drug for the treatment of atrial fibrillation. Expert Opin Investig Drugs 2000; 9:2695-2704.
8. Saliba WI. Dofetilide (Tikosyn): A new drug to control atrial fibrillation. Cleve Clinic J Med 2001; 68:353-363.
9. Elming H, Brendorp B, Pedersen OD, Kober L, Torp-Petersen C. Dofetilide: A new drug to control cardiac arrhythmia. Expert Opin Pharmacother 2003; 4:973-985.
10. Pedersen OD, Bagger H, Keller N, Marchant B, Kober I, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigation of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation 2001; 104:292-296.
11. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videback J, Marchant B, Camm AJ. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Eng J Med 1999; 341:857-865.